POM Wonderful Asks Court To Vacate “Draconian” FTC Order
This article was originally published in The Tan Sheet
Executive Summary
The nearly three-year battle between FTC and POM Wonderful moves to a federal appeals court, where the pomegranate juice and supplement firm asks the judges to nix the commission’s order that POM conduct two randomized controlled trials to support disease-related health claims.
You may also be interested in...
Court Upholds FTC Order Against POM, But Scrutinizes Clinical Trial Requirement
The U.S. Court of Appeals for the District of Columbia Circuit on Jan. 30 issued a ruling largely upholding the FTC’s 2012 order against POM, but said the agency’s argument fails “scrutiny insofar as it categorically requires two RCTs for all disease-related claims.”
Court Upholds FTC Order Against POM, But Scrutinizes Clinical Trial Requirement
The U.S. Court of Appeals for the District of Columbia Circuit on Jan. 30 issued a ruling largely upholding the FTC’s 2012 order against POM, but said the agency’s argument fails “scrutiny insofar as it categorically requires two RCTs for all disease-related claims.”
Advocacy Groups Say POM Claims Prey On Consumer Desperation
“Consumers may be desperate to find a cure or treatment for their disease when conventional treatment has not worked … and turn to food products or dietary supplements,” CSPI and Public Citizen attorneys say in an amicus brief supporting FTC’s enforcement against POM.